Relmada Therapeutics, Inc. RLMD Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s change in AP?
- Relmada Therapeutics, Inc. (RLMD) reported change in AP of $1.76M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s change in AP changed year-over-year?
- Relmada Therapeutics, Inc.'s change in AP increased by 161.5% year-over-year, from -$2.87M to $1.76M.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.